Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1994 3
1995 1
1996 2
1997 2
1998 3
1999 2
2000 4
2001 1
2002 4
2003 4
2004 7
2005 13
2006 7
2007 12
2008 8
2009 10
2010 8
2011 10
2012 6
2013 5
2014 4
2015 3
2016 6
2017 7
2018 5
2019 10
2020 16
2021 19
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

167 results
Results by year
Filters applied: . Clear all
Page 1
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Ozatilgan A, Geffriaud-Ricouard C, Castellano D; CARD Investigators. de Wit R, et al. Among authors: wulfing c. N Engl J Med. 2019 Dec 26;381(26):2506-2518. doi: 10.1056/NEJMoa1911206. Epub 2019 Sep 30. N Engl J Med. 2019. PMID: 31566937 Clinical Trial.
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
Fizazi K, Kramer G, Eymard JC, Sternberg CN, de Bono J, Castellano D, Tombal B, Wülfing C, Liontos M, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Oudard S, Facchini G, Poole EM, Ozatilgan A, Geffriaud-Ricouard C, Bensfia S, de Wit R. Fizazi K, et al. Among authors: wulfing c. Lancet Oncol. 2020 Nov;21(11):1513-1525. doi: 10.1016/S1470-2045(20)30449-6. Epub 2020 Sep 11. Lancet Oncol. 2020. PMID: 32926841 Clinical Trial.
Eine randomisierte, offene, Multizenterstudie zum Einsatz von Cabazitaxel versus einem Androgenrezeptor (AR)-gerichteten Präparat (Abirateron oder Enzalutamid) bei Patienten mit mCRPC nach Vorbehandlung mit Docetaxel und frühem Nicht-Ansprechen nach AR-gerichtetem Präparat (CARD) – Studie AP 97/17 der AUO.
Rexer H, Graefen M, Wülfing C. Rexer H, et al. Among authors: wulfing c. Aktuelle Urol. 2018 Jun;49(3):222-224. doi: 10.1055/a-0596-4618. Epub 2018 May 22. Aktuelle Urol. 2018. PMID: 29788522 German. No abstract available.
Visualizing T-cell recognition.
Davis MM, Wülfing C, Krummel MF, Savage PA, Xu J, Sumen C, Dustin ML, Chien YH. Davis MM, et al. Among authors: wulfing c. Cold Spring Harb Symp Quant Biol. 1999;64:243-51. doi: 10.1101/sqb.1999.64.243. Cold Spring Harb Symp Quant Biol. 1999. PMID: 11232292 Review. No abstract available.
New TACTICS for finding Numb.
Roybal KT, Wülfing C. Roybal KT, et al. Among authors: wulfing c. Immunol Cell Biol. 2013 Jan;91(1):1-2. doi: 10.1038/icb.2012.63. Epub 2012 Nov 27. Immunol Cell Biol. 2013. PMID: 23183270 Review. No abstract available.
Systems Imaging of the Immune Synapse.
Ambler R, Ruan X, Murphy RF, Wülfing C. Ambler R, et al. Among authors: wulfing c. Methods Mol Biol. 2017;1584:409-421. doi: 10.1007/978-1-4939-6881-7_25. Methods Mol Biol. 2017. PMID: 28255716 Free PMC article.
167 results